Journal ArticleDOI
Pregnancy outcome after cabergoline treatment in early weeks of gestation
Elena Ricci,Fabio Parazzini,Fabio Parazzini,T. Motta,Carlo Ferrari,Annamaria Colao,Antonio Clavenna,Francesca Rocchi,Emanuela Gangi,Sandra Paracchi,Maurizio Gasperi,Maurizio Lavezzari,Anna Elisa Nicolosi,Simona Ferrero,Maria Luisa Landi,Paolo Beck-Peccoz,Maurizio Bonati +16 more
TLDR
The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline.About:
This article is published in Reproductive Toxicology.The article was published on 2002-11-01. It has received 144 citations till now. The article focuses on the topics: Pregnancy & Gestational age.read more
Citations
More filters
Journal ArticleDOI
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Felipe F. Casanueva,Mark E. Molitch,Janet A. Schlechte,Roger Abs,Vivien Bonert,Marcello D. Bronstein,Thierry Brue,Paolo Cappabianca,Annamaria Colao,Rudolf Fahlbusch,Hugo L. Fideleff,Moshe Hadani,Paul A. Kelly,David L. Kleinberg,Edward R. Laws,Josef Marek,Maurice F. Scanlon,Luís G. Sobrinho,John Wass,Andrea Giustina +19 more
TL;DR: These guidelines represent the current recommendations on the diagnosis and management of prolactinomas based upon comprehensive analysis and synthesis of all available data.
Journal ArticleDOI
Advances in the treatment of prolactinomas.
TL;DR: A critical analysis of the efficacy and safety of the various modes of therapy available for the treatment of patients with prolactinomas with an emphasis on challenging situations is provided, a discussion of the data regarding withdrawal of medical therapy, and a foreshadowing of novel approaches to therapy that may become available in the future.
Journal ArticleDOI
Hyperprolactinemia and prolactinomas.
TL;DR: Any process interfering with dopamine synthesis, its transport to the pituitary gland, or its action at the level of lactotroph dopamine receptors can cause hyperprolactinemia, and hyper Prolactinomas can have clinical effects not only on the reproductive axis.
Journal Article
Diagnosis and management of hyperprolactinemia
TL;DR: The diagnostic approach and management of hyperprolactinemia in various clinical settings are described, with emphasis on newer diagnostic strategies and the role of various therapeutic options, including treatment with selective dopamine agonists.
References
More filters
Journal ArticleDOI
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Jonathan Webster,Gabriella Piscitelli,Anna Polli,Carlo Ferrari,Ikram Shah Bin Ismail,Maurice F. Scanlon +5 more
TL;DR: Cabergoline is more effective and better tolerated than bromocriptine in women with hyperprolactinemic amenorrhea and Gastrointestinal symptoms were significantly less frequent, less severe, and shorter-lived in the women treated with cabergoline.
Journal ArticleDOI
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Johan Verhelst,Roger Abs,Dominique Maiter,Annick Van den Bruel,Mark Vandeweghe,Brigitte Velkeniers,Jean Mockel,G. Lamberigts,Patrick Petrossians,Peter Coremans,Charles Mahler,Achille Stevenaert,Jan Verlooy,Christian Raftopoulos,Albert Beckers +14 more
TL;DR: The high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia is confirmed, in a large-scale retrospective study, leaving few patients with unacceptable side effects or inadequate clinical response.
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group
TL;DR: Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic amenorrhea.
Journal ArticleDOI
Surveillance of Bromocriptine in Pregnancy
TL;DR: The data suggest that the intake of bromocriptine during pregnancy is not associated with an increased risk to the fetus.
Journal ArticleDOI
Pregnancy outcome after treatment with the ergot derivative, cabergoline
TL;DR: Investigated in different animal species, cabergoline showed no teratogenic or embryotoxic effects on rabbits, and considering the dose envisaged for humans, large safety margins exist.